Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model

ConclusionsThe results suggest that PR-PFD could be a promising drug for the prevention and treatment of cardiac steatosis and fibrosis induced by obesity.

Source: Cardiovascular Drugs and Therapy - July 2, 2020 Category: Cardiology Source Type: research